(1R,2R)-2-(pent-4-en-1-yl)cyclopropyl acetate | 1384277-03-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,2R)-2-(pent-4-en-1-yl)cyclopropyl acetate
• 英文别名: [(1R,2R)-2-pent-4-enylcyclopropyl] acetate
• CAS: 1384277-03-5
• 化学式: C₁₀H₁₆O₂
• 分子量: 168.236
• InChiKey: VSWXTKBHQYCTDE-NXEZZACHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R,2R)-2-(pent-4-en-1-yl)cyclopropyl acetate 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 (1R,2R)-2-(pent-4-en-1-yl)cyclopropanol 、 (1S,2S)-2-(pent-4-en-1-yl)cyclopropanol
  参考文献：
  名称：

  Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

  摘要：

  A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.

  DOI：

  10.1021/ml300017p
• 作为产物：
  描述：

  (E)-1-trimethylsilyloxy-1,6-heptadiene 在 吡啶 、 四丁基氟化铵 、 diethylzinc 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 甲苯 为溶剂， 反应 7.25h， 生成 (1R,2R)-2-(pent-4-en-1-yl)cyclopropyl acetate 、 (1S,2S)-2-(pent-4-en-1-yl)cyclopropyl acetate
  参考文献：
  名称：

  Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

  摘要：

  A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.

  DOI：

  10.1021/ml300017p

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：GILEAD SCIENCES INC

  公开号：WO2014008285A1

  公开（公告）日：2014-01-09

  Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

  化合物I的结构已经披露，以及其药用盐。还披露了使用这些化合物的方法和含有这些化合物的药物组合物。
• INHIBITORS OF HEPATITIS C VIRUS
  申请人：Gilead Sciences, Inc.

  公开号：EP2870160B1

  公开（公告）日：2016-09-28
• US9296782B2
  申请人：——

  公开号：US9296782B2

  公开（公告）日：2016-03-29
• US9655944B2
  申请人：——

  公开号：US9655944B2

  公开（公告）日：2017-05-23